<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancerToshiyuki Hirano, Kenzo Soejima, Hiroyuki Yasuda et al.|Oncotarget|2015Cited by 159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, David A. Barbie, Tetsuo Tani et al.|Cancer Cell|2022Cited by 101
<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Haritha Mathsyaraja et al.|Cancer Discovery|2024Cited by 98
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H. Knelson, David A. Barbie, Elena V. Ivanova et al.|Cancer Immunology Research|2022Cited by 88
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Research|2016Cited by 73